PMID- 16234335
OWN - NLM
STAT- MEDLINE
DCOM- 20060321
LR  - 20161124
IS  - 0305-7453 (Print)
IS  - 0305-7453 (Linking)
VI  - 56
IP  - 6
DP  - 2005 Dec
TI  - In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect 
      filler.
PG  - 1063-8
AB  - OBJECTIVES: Impregnation of antimicrobial agents within biodegradable carriers 
      with osteoconductive properties could provide the means for one-stage surgical 
      treatment of osteomyelitis. In this study, the in vitro and in vivo antibiotic 
      release from this type of bone defect filler was characterized. METHODS: 
      Cylindrical pellets (2.5 x 1.5 mm) were manufactured from bioabsorbable 
      poly(L-lactide-co-glycolide) (PLGA) matrix, ciprofloxacin [8.3 +/- 0.1% (w/w)] 
      and osteoconductive bioactive glass microspheres (90-125 microm) [27 +/- 2% 
      (w/w)]. In vitro studies were carried out to delineate the release profile of the 
      antibiotic. The antimicrobial activity of the release antibiotic was verified 
      with MIC testing. In a time-sequence study in the rabbit, pellets were surgically 
      implanted in the proximal tibia and the antibiotic concentrations achieved in 
      bone were measured at 1, 2, 3, 4, 5 and 6 months. RESULTS: In vitro elution 
      studies showed sustained release of ciprofloxacin at a therapeutic level (>2 
      microg/mL) over a time period of 4 months. The released ciprofloxacin had 
      maintained its antimicrobial capacity against five standard ATCC strains. In 
      vivo, the delivery system produced high local bone concentrations (247.9 +/- 91.0 
      mug/g of bone) for a time period of 3 months with no significant systemic 
      exposure. Histomorphometry and micro-CT imaging confirmed new bone formation 
      around the pellets within 3 months as a sign of an independent osteoconductive 
      property of the composite. CONCLUSIONS: The tested composite seems to be a 
      promising option for local therapy of surgically treated bone infections. The 
      main advantages are the antibiotic release for a definite time period with 
      therapeutic concentrations, which may minimize slow residual release at 
      suboptimal concentrations.
FAU - Makinen, Tatu J
AU  - Makinen TJ
AD  - Orthopaedic Research Unit, Department of Orthopaedic Surgery and Traumatology, 
      University of Turku, Medisiina B4, Kiinamyllynkatu 10, 20520 Turku, Finland.
FAU - Veiranto, Minna
AU  - Veiranto M
FAU - Lankinen, Petteri
AU  - Lankinen P
FAU - Moritz, Niko
AU  - Moritz N
FAU - Jalava, Jari
AU  - Jalava J
FAU - Tormala, Pertti
AU  - Tormala P
FAU - Aro, Hannu T
AU  - Aro HT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051018
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bone Substitutes)
RN  - 0 (Delayed-Action Preparations)
RN  - 34346-01-5 (Polyglactin 910)
RN  - 5E8K9I0O4U (Ciprofloxacin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/administration & 
      dosage/analysis/pharmacokinetics/pharmacology
MH  - Bone Substitutes/*chemistry
MH  - Bone and Bones/chemistry/diagnostic imaging
MH  - Ciprofloxacin/*administration & dosage/analysis/*pharmacokinetics/pharmacology
MH  - Delayed-Action Preparations
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Microspheres
MH  - Models, Animal
MH  - Osteogenesis
MH  - Osteomyelitis/*drug therapy/surgery
MH  - Polyglactin 910
MH  - Rabbits
MH  - Radiography
EDAT- 2005/10/20 09:00
MHDA- 2006/03/22 09:00
CRDT- 2005/10/20 09:00
PHST- 2005/10/20 09:00 [pubmed]
PHST- 2006/03/22 09:00 [medline]
PHST- 2005/10/20 09:00 [entrez]
AID - dki366 [pii]
AID - 10.1093/jac/dki366 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2005 Dec;56(6):1063-8. doi: 10.1093/jac/dki366. Epub 2005 
      Oct 18.